Leverage biomaterials to modulate immunity for type 1 diabetes
Open Access
- 2 November 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 997287
Abstract
The pathogeny of type 1 diabetes (T1D) is mainly provoked by the β-cell loss due to the autoimmune attack. Critically, autoreactive T cells firsthand attack β-cell in islet, that results in the deficiency of insulin in bloodstream and ultimately leads to hyperglycemia. Hence, modulating immunity to conserve residual β-cell is a desirable way to treat new-onset T1D. However, systemic immunosuppression makes patients at risk of organ damage, infection, even cancers. Biomaterials can be leveraged to achieve targeted immunomodulation, which can reduce the toxic side effects of immunosuppressants. In this review, we discuss the recent advances in harness of biomaterials to immunomodulate immunity for T1D. We investigate nanotechnology in targeting delivery of immunosuppressant, biological macromolecule for β-cell specific autoreactive T cell regulation. We also explore the biomaterials for developing vaccines and facilitate immunosuppressive cells to restore immune tolerance in pancreas.Keywords
Funding Information
- Science, Technology and Innovation Commission of Shenzhen Municipality (JCYJ20200109142610136)
- National Natural Science Foundation of China (31971268)
- Basic and Applied Basic Research Foundation of Guangdong Province (2019A1515010855)
- National Natural Science Foundation of China-Guangdong Joint Fund (2020A1515010802)
- Basic and Applied Basic Research Foundation of Guangdong Province (2020A1515110166)
- National Natural Science Foundation of China-Guangdong Joint Fund (No.2020A1515010802)
- Shenzhen Science and Technology Innovation Program (Grant No. RCYX20200714114643121)
- Shenzhen Municipal Fundamental Research Program (JCYJ20180507181654186)
- Fundamental Research Funds for the Central Universities (19lgzd45)
This publication has 169 references indexed in Scilit:
- Macrophage plasticity and polarization: in vivo veritasJournal of Clinical Investigation, 2012
- A Short Pulse of IL-4 Delivered by DCs Electroporated With Modified mRNA Can Both Prevent and Treat Autoimmune Diabetes in NOD MiceMolecular Therapy, 2010
- The potential role of indoleamine 2,3 dioxygenase (IDO) as a predictive and therapeutic target for diabetes treatment: a mythical truthEPMA Journal, 2010
- Genetic-induced Variations in the GAD65 T-cell Repertoire Governs Efficacy of Anti-CD3/GAD65 Combination Therapy in New-onset Type 1 DiabetesMolecular Therapy, 2010
- Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety studyClinical and Experimental Immunology, 2008
- Macrophage diversity in renal injury and repairJournal of Clinical Investigation, 2008
- Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune DestructionImmunity, 2008
- Dendritic cell–expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD miceJournal of Experimental Medicine, 2007
- CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cellsJournal of Experimental Medicine, 2006
- Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing TregsJournal of Clinical Investigation, 2006